Tag Archives: VBLT

Chardan Capital Keeps Their Buy Rating on Vascular Biogenics (VBLT)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3.25. The company’s shares closed last Monday at $1.15. According to TipRanks.com, Livshits is

H.C. Wainwright Remains a Buy on Vascular Biogenics (VBLT)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $1.04. According to TipRanks.com, Ramakanth has

Vascular Biogenics (VBLT) Gets a Buy Rating from JonesTrading

JonesTrading analyst Soumit Roy reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3.75. The company’s shares closed last Monday at $0.95, close to its 52-week low of $0.90. According to

H.C. Wainwright Sticks to Their Buy Rating for Vascular Biogenics (VBLT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $3.00. The company’s shares closed last Monday at $1.23. According to TipRanks.com, Ramakanth ‘s ranking currently consits

Chardan Capital Reiterates a Hold Rating on Vascular Biogenics (VBLT)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Hold rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3. The company’s shares closed last Monday at $1.17. According to TipRanks.com, Livshits is

Chardan Capital Sticks to Their Hold Rating for Vascular Biogenics (VBLT)

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Hold rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.21. Livshits observed: “We understand the colon